摘要
目的探讨超声弹性成像联合血清ENO1抗体对乳腺癌的诊断价值。方法选择本院2017年7月—2020年7月经病理确诊的乳腺癌患者72例,根据临床分期分组:Ⅰ期+Ⅱ期23例,Ⅲ期34例,Ⅳ期15例。另选同期乳腺良性疾病患者39例及健康体检者40例作为对照组,比较3组人群血清ENO1抗体水平,以病理检查结果作为“金标准”,比较血清ENO1抗体、超声弹性成像单一及联合检测对乳腺癌的诊断价值。结果乳腺癌组ENO1抗体水平高于乳腺良性疾病组和健康对照组,且升高水平与患者年龄、临床分期均无关。绘制ENO1抗体诊断乳腺癌的ROC曲线,得到ENO1抗体诊断乳腺癌的cut-off值为32.78 ng/ml,AUC为0.733,灵敏度为58.3%,特异度为89.7%。两者联合检测诊断乳腺癌的灵敏度为95.8%、特异度为84.6%,优于单一检测。结论超声弹性成像和血清ENO1抗体对乳腺癌的诊断均有一定的准确性,两者联合检测能大大提高灵敏度,降低乳腺癌的漏诊率。
Objective To explore the diagnostic value of ultrasound elastography combined with serum ENO1 antibody for breast cancer. Methods Seventy-two cases of breast cancer diagnosed by pathology were selected in our hospital from July 2017 to July 2020,and divided into three groups according to clinical stages( 23 cases of stage Ⅰ+ Ⅱ,34 cases of stage Ⅲ,and 15 cases of stage Ⅳ). A total of 39 patients with benign breast disease and 40 healthy subjects were selected as the control group.The level of serum ENO1 antibody was compared in the three groups. The results of pathological examination were used as the“gold standard”to compare the diagnostic value of serum ENO1 antibody and ultrasonic elastography single detection and combined detection for breast cancer. Results The level of ENO1 antibody in the breast cancer group was higher than that in the benign breast disease group and the control group,and the increased level was not related to the age and clinical stage of the patients. The ROC curve of ENO1 antibody in the diagnosis of breast cancer was drawn,and the cut-off value was32. 78 ng/ml,the AUC was 0. 733,the sensitivity was 58. 3%,and the specificity was 89. 7%. The sensitivity and specificity of the combined detection of ENO1 antibody and ultrasonic elastography were 95. 8% and 84. 6% in the diagnosis of breast cancer,which were better than that of the single detection. Conclusion Both ultrasound elastography and serum ENO1 antibody have certain accuracy in the diagnosis of breast cancer,and the combined detection of the two indicators can greatly improve the sensitivity and reduce the rate of missed diagnosis of breast cancer.
作者
张丽敏
王怡悦
钟慧欲
ZHANG Li-min;WANG Yi-yue;ZHONG Hui-yu(Department of Ultrasound,Longquan People's Hospital,Longquan,Zhejiang 323700,China;不详)
出处
《中国卫生检验杂志》
CAS
2022年第2期209-211,共3页
Chinese Journal of Health Laboratory Technology